These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 15295684)

  • 21. [The treatment of idiopathic pulmonary artery hypertension and its relation to systemic scleroderma].
    Humbert M
    Rev Med Interne; 2007 Dec; 28 Suppl 4():S273-6. PubMed ID: 17961866
    [No Abstract]   [Full Text] [Related]  

  • 22. Sildenafil extends survival and graft function in a large animal lung transplantation model.
    Korom S; Hillinger S; Cardell M; Zhai W; Tan Q; Dutly A; Leskosek B; Weder W
    Eur J Cardiothorac Surg; 2006 Mar; 29(3):288-93. PubMed ID: 16442298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pulmonary hypertension: inhaled nitric oxide, sildenafil and natriuretic peptides.
    Steiner MK; Preston IR; Klinger JR; Hill NS
    Curr Opin Pharmacol; 2005 Jun; 5(3):245-50. PubMed ID: 15907910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
    Mathai SC; Girgis RE; Fisher MR; Champion HC; Housten-Harris T; Zaiman A; Hassoun PM
    Eur Respir J; 2007 Mar; 29(3):469-75. PubMed ID: 17079256
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition.
    Botha P; Parry G; Dark JH; Macgowan GA
    J Heart Lung Transplant; 2009 Jul; 28(7):676-82. PubMed ID: 19560695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sildenafil citrate therapy for pulmonary arterial hypertension.
    Galiè N; Ghofrani HA; Torbicki A; Barst RJ; Rubin LJ; Badesch D; Fleming T; Parpia T; Burgess G; Branzi A; Grimminger F; Kurzyna M; Simonneau G;
    N Engl J Med; 2005 Nov; 353(20):2148-57. PubMed ID: 16291984
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sildenafil increases cerebrovascular reactivity: a transcranial Doppler study.
    Brenner S
    Neurology; 2006 May; 66(9):1455-6; author reply 1455-6. PubMed ID: 16682690
    [No Abstract]   [Full Text] [Related]  

  • 28. Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease.
    Schulze-Neick I; Hartenstein P; Li J; Stiller B; Nagdyman N; Hübler M; Butrous G; Petros A; Lange P; Redington AN
    Circulation; 2003 Sep; 108 Suppl 1():II167-73. PubMed ID: 12970227
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Cardio-vascular effects of sildenafil: new data].
    Danchin N
    Ann Cardiol Angeiol (Paris); 2002 Dec; 51(6):341-5. PubMed ID: 12608126
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension.
    Sebkhi A; Strange JW; Phillips SC; Wharton J; Wilkins MR
    Circulation; 2003 Jul; 107(25):3230-5. PubMed ID: 12796132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells.
    Wharton J; Strange JW; Møller GM; Growcott EJ; Ren X; Franklyn AP; Phillips SC; Wilkins MR
    Am J Respir Crit Care Med; 2005 Jul; 172(1):105-13. PubMed ID: 15817798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sildenafil improves walk distance in idiopathic pulmonary fibrosis.
    Collard HR; Anstrom KJ; Schwarz MI; Zisman DA
    Chest; 2007 Mar; 131(3):897-899. PubMed ID: 17356110
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sildenafil modulates hemodynamics and pulmonary gas exchange.
    Kleinsasser A; Loeckinger A; Hoermann C; Puehringer F; Mutz N; Bartsch G; Lindner KH
    Am J Respir Crit Care Med; 2001 Feb; 163(2):339-43. PubMed ID: 11179103
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of pulmonary arterial hypertension with sildenafil: from pathophysiology to clinical evidence.
    Raja SG; Danton MD; MacArthur KJ; Pollock JC
    J Cardiothorac Vasc Anesth; 2006 Oct; 20(5):722-35. PubMed ID: 17023298
    [No Abstract]   [Full Text] [Related]  

  • 35. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension.
    Blanco I; Gimeno E; Munoz PA; Pizarro S; Gistau C; Rodriguez-Roisin R; Roca J; Barberà JA
    Am J Respir Crit Care Med; 2010 Feb; 181(3):270-8. PubMed ID: 19875684
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of type-5 phosphodiesterase: promising therapy for pulmonary hypertension.
    Watanabe H
    Intern Med; 2004 Oct; 43(10):891-3. PubMed ID: 15575233
    [No Abstract]   [Full Text] [Related]  

  • 37. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
    Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
    Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension.
    Lewis GD; Shah R; Shahzad K; Camuso JM; Pappagianopoulos PP; Hung J; Tawakol A; Gerszten RE; Systrom DM; Bloch KD; Semigran MJ
    Circulation; 2007 Oct; 116(14):1555-62. PubMed ID: 17785618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined use of PDE5 inhibitors and nitrates in the treatment of pulmonary arterial hypertension in patients with heart failure.
    Stehlik J; Movsesian MA
    J Card Fail; 2009 Feb; 15(1):31-4. PubMed ID: 19181291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term therapy of interferon-alpha induced pulmonary arterial hypertension with different PDE-5 inhibitors: a case report.
    Jochmann N; Kiecker F; Borges AC; Hofmann MA; Eddicks S; Sterry W; Baumann G; Trefzer U
    Cardiovasc Ultrasound; 2005 Sep; 3():26. PubMed ID: 16138923
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.